Dean A Fennell

Summary

Affiliation: Queen Mary
Country: UK

Publications

  1. ncbi Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma
    Dean A Fennell
    Lung and Mesothelioma Unit, Department of Medical Oncology, St Bartholomew s Hospital, West Smithfield, London EC1A 7BE, United Kingdom
    Lung Cancer 47:277-81. 2005
  2. ncbi Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development
    Dean A Fennell
    Department of Medical Oncology, Lung Cancer and Mesothelioma Research Group, St Bartholomew s Hospital, West Smithfield, London, UK
    Lancet Oncol 5:354-62. 2004
  3. ncbi Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials
    Dean A Fennell
    Lung Cancer and Mesthelioma Unit, Department of Oncology, and the Institute of Cell and Molecular Science Pathology, St Bartholomew s Hospital, London, United Kingdom
    J Clin Oncol 23:184-9. 2005
  4. ncbi Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma
    Dean A Fennell
    Lung and Mesothelioma Unit, Department of Medical Oncology, St Bartholomew s Hospital, West Smithfield, London, UK
    Cancer 109:93-9. 2007
  5. ncbi Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer
    Dean A Fennell
    Department of Medical Oncology, St Bartholomew s Hospital, London, United Kingdom
    Int J Cancer 121:2575-7. 2007
  6. ncbi Prognostic factors in mesothelioma
    Jeremy P C Steele
    Mesothelioma Unit, Department of Medical Oncology, St Bartholomew s Hospital and Medical College, London EC1A 7BE, UK
    Lung Cancer 49:S49-52. 2005
  7. ncbi Pulmonary toxicity and cancer treatment
    Dean A Fennell
    Lung Cancer and Mesothelioma Research Group, Department of Medical Oncology, St Bartholomew's Hospital, London
    Hosp Med 65:462-5. 2004
  8. ncbi In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy
    Bryone J Kuss
    Institute of Child Health, University College London, London, United Kingdom
    Int J Cancer 98:128-33. 2002
  9. ncbi Advances in the systemic therapy of malignant pleural mesothelioma
    Dean A Fennell
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, 97 Liburn Road, Belfast BT9 7BL, Northern Ireland, UK
    Nat Clin Pract Oncol 5:136-47. 2008
  10. ncbi In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion
    Peter W Szlosarek
    Cancer Research UK Translational Oncology Laboratory, Barts and The London, UK
    Clin Cancer Res 12:7126-31. 2006

Collaborators

Detail Information

Publications15

  1. ncbi Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma
    Dean A Fennell
    Lung and Mesothelioma Unit, Department of Medical Oncology, St Bartholomew s Hospital, West Smithfield, London EC1A 7BE, United Kingdom
    Lung Cancer 47:277-81. 2005
    ..CONCLUSION: VO has activity in MPM with most patients responding or having stable disease, although this doublet is associated with significant toxicity...
  2. ncbi Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development
    Dean A Fennell
    Department of Medical Oncology, Lung Cancer and Mesothelioma Research Group, St Bartholomew s Hospital, West Smithfield, London, UK
    Lancet Oncol 5:354-62. 2004
    ..This review discusses recent developments in apoptosis biology that are specific to mesothelioma and the therapeutic implications for this aggressive cancer...
  3. ncbi Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials
    Dean A Fennell
    Lung Cancer and Mesthelioma Unit, Department of Oncology, and the Institute of Cell and Molecular Science Pathology, St Bartholomew s Hospital, London, United Kingdom
    J Clin Oncol 23:184-9. 2005
    ..Our retrospective analysis set out to test the validity of the model as a prognostic tool in patients treated in three phase II trials at St Bartholomew's Hospital (London, United Kingdom) between 1999 and 2003...
  4. ncbi Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma
    Dean A Fennell
    Lung and Mesothelioma Unit, Department of Medical Oncology, St Bartholomew s Hospital, West Smithfield, London, UK
    Cancer 109:93-9. 2007
    ..Malignant pleural mesothelioma (MPM) is a rapidly progressive lethal tumor. Treatment options remain limited and the outcome in recurrent disease is poor...
  5. ncbi Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer
    Dean A Fennell
    Department of Medical Oncology, St Bartholomew s Hospital, London, United Kingdom
    Int J Cancer 121:2575-7. 2007
    ..3). QoL showed improvement in activity symptoms and stabilization of physical symptoms. As IPM was a well-tolerated regimen with activity in rSCLC, a phase III trial comparing this triplet with other regimens in this setting is warranted...
  6. ncbi Prognostic factors in mesothelioma
    Jeremy P C Steele
    Mesothelioma Unit, Department of Medical Oncology, St Bartholomew s Hospital and Medical College, London EC1A 7BE, UK
    Lung Cancer 49:S49-52. 2005
    ..9 months [95% C.I.=8.5-11.3] for those in the worst group. The suggestion is that all clinical and biological factors relevant to prognosis should be recorded prospectively in mesothelioma patients selected for clinical trials...
  7. ncbi Pulmonary toxicity and cancer treatment
    Dean A Fennell
    Lung Cancer and Mesothelioma Research Group, Department of Medical Oncology, St Bartholomew's Hospital, London
    Hosp Med 65:462-5. 2004
    ..This article discusses the mechanisms, common clinical features and risk factors for cytotoxic drug-induced pulmonary toxicity, and outlines general management principles...
  8. ncbi In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy
    Bryone J Kuss
    Institute of Child Health, University College London, London, United Kingdom
    Int J Cancer 98:128-33. 2002
    ..It provides rationale for the investigation of therapy adjuvants such as antisense oligonucleotides in the treatment of this malignancy...
  9. ncbi Advances in the systemic therapy of malignant pleural mesothelioma
    Dean A Fennell
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, 97 Liburn Road, Belfast BT9 7BL, Northern Ireland, UK
    Nat Clin Pract Oncol 5:136-47. 2008
    ..Coupled with high-quality translational research, such developments have real potential to improve the outlook of patients at a time of increasing incidence...
  10. ncbi In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion
    Peter W Szlosarek
    Cancer Research UK Translational Oncology Laboratory, Barts and The London, UK
    Clin Cancer Res 12:7126-31. 2006
    ..A phase II clinical trial is planned to evaluate the role of arginine depletion in patients with AS-negative MPM...
  11. ncbi Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma
    Andrea Sartore Bianchi
    Institute of Internal Medicine and Medical Oncology, IRCCS Policlinico San Matteo University Hospital, 1 27100 Pavia corrected Italy
    Clin Cancer Res 13:5942-51. 2007
    ..We aimed at verifying whether the proteasome inhibitor Bortezomib could abrogate NF-kappaB activity in MMe cells, leading to tumor cell death and may be established as a novel treatment for this aggressive neoplasm...
  12. ncbi Molecular and Immunological approaches
    Dean A Fennell
    Centre for Cancer Research and Cell Biology, Queen's University, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland
    Lung Cancer 49:S87. 2005
  13. ncbi PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism
    Deborah E Banker
    Clinical Research Division, FHCRC, D1 100, 1124 Columbia Street, Seattle, WA 98104, USA
    Leuk Res 26:91-106. 2002
    ..Therefore, PK11195 might contribute to improved clinical outcomes in AML...
  14. ncbi Caspase regulation in non-small cell lung cancer and its potential for therapeutic exploitation
    Dean A Fennell
    Thoracic Oncology Research Group, Centre for Cancer Research and Cell Biology, Oncology, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland
    Clin Cancer Res 11:2097-105. 2005
    ..This review discusses current knowledge relating to caspase regulation in NSCLC and highlights novel strategies for reversing the apoptosis resistant phenotype, with potential to accelerate development of effective therapy...
  15. ncbi Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL
    Sandra Van Schaeybroeck
    Drug Resistance Group, Center for Cancer Research and Cell Biology, Queen s University Belfast, Belfast, Northern Ireland
    Cancer Res 68:8312-21. 2008
    ....